Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 7, 2014, Pages 773-777

  Sonenthal, Paul D ^a,b,c   Ratshaa, Bakgaki ^a   Chimbengo, Gilbert ^a   Rantleru, Tumelo ^a   Ngoni, Thelma ^a   Barenbaum, Sarah ^a,d   Platoff, Rebecca ^a,d   Steenhoff, Andrew P ^a,e   Gross, Robert ^a,c,f  

^a BOTSWANA UPENN PARTNERSHIP   (Botswana)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse effects; Efavirenz; Highly active antiretroviral therapy; HIV; Pharmacoepidemiology

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ADVERSE DRUG REACTION; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDERS IDENTIFICATION TEST; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CHECKLIST; COHORT ANALYSIS; DEPRESSION; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOOD MODULE THE PRIMARY CARE EVALUATION OF MENTAL DISORDER; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; WEIGHT; WEIGHT GAIN; BODY WEIGHT; DRINKING BEHAVIOR; DRUG COMBINATION; FOLLOW UP; HIV INFECTIONS; MIDDLE AGED;

ADULT; ALCOHOL DRINKING; ANTI-HIV AGENTS; BENZOXAZINES; BODY WEIGHT; BOTSWANA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84903815056     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3615     Document Type: Article

References (14)

1. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15(16): 2109-2117.
2. Gross R, Yip B, Lo Re V, 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006; 194(8): 1108-1114.
3. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50(5): 529-536.
4. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34(4): 407-414.
5. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28(5): 445-449.
6. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010; 50(5): 787-791.
7. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011; 15(8): 1803-1818.
8. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143(10): 714-721.
9. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18(18): 2391-2400.
10. Lawler K, Mosepele M, Seloilwe E, et al. Depression among HIV-positive individuals in Botswana: a behavioral surveillance. AIDS Behav 2011; 15(1): 204-208.
11. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158(16): 1789-1795.
12. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38(5): 560-565.
13. Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008; 49(3): 336-337.
14. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr 2006; 42(4): 514-515.